GenFleet Therapeutics (02595.HK) Surges Over 6% as GDF15/IL-6 Bispecific Antibody GFS202A Receives CDE Clinical Trial Acceptance
May 20, 2026 11:16
CST Updated
11:32
GenFleet Therapeutics
Innovative Drug Developer